Taxotere(R) Receives U.S. FDA Approval For The Treatment Of Patients With Head And Neck Cancer

... Sanofi-aventis announced today that following a priority review of a supplemental new drug application (sNDA), the U.S. Food and Drug Administration (FDA) has approved Taxotere(R) (docetaxel) Injection Concentrate in combination with cisplatin and fluorouracil for the induction treatment of patients with inoperable locally advanced squamous cell carcinoma of the head and neck (SCCHN). [click link for full article] ...